Ignite Creation Date:
2024-05-05 @ 10:23 AM
Last Modification Date:
2024-10-26 @ 9:03 AM
Study NCT ID:
NCT00002446
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
Safety and Effectiveness of Fluconazole Versus SCH 56592 to Treat Thrush in HIV-Positive Patients
Sponsor:
Schering-Plough
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
Randomized Controlled Trial of SCH 56592 Oral Suspension Versus Fluconazole Suspension in the Treatment of Oropharyngeal Candidiasis OPC in HIV-Positive Patients
Status:
COMPLETED
Status Verified Date:
2000-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to compare the safety and effectiveness of 2 treatments for thrush a fungal infection of the mouth and throat in HIV-positive patients Fluconazole is a drug that is commonly used to treat thrush SCH 56592 is a new drug that will be compared to fluconazole
Detailed Description:
Patients receive SCH 56592 oral suspension or fluconazole suspension for 14 days Patients remain on study for 44 days total and are monitored for safety and efficacy of study treatment
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| I97-331 | None | None | None |
| C97-331 | None | None | None |